A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Skyrizi – partnered with Boehringer Ingelheim – is already enjoying rapid growth from its approved uses in psoriasis, psoriatic arthritis and Crohn’s disease, with sales rising 76% to $5.2 ...

NEW YORK — Skyrizi exhibited efficacy across racial and ethnic groups for the treatment of moderate to severe plaque psoriasis, according to a presentation at the Skin of Color Update 2023 ...

Citing results published by the British Journal of Dermatology in a head-to-head study, AbbVie’s Skyrizi was deemed more effective when compared to Amgen’s Otezla among adult patients with moderate ...

AbbVie (ABBV) said Wednesday its FDA-approved immunology therapy, Skyrizi, outperformed Amgen’s (AMGN) blockbuster therapy, Otezla in plaque psoriasis. Read more here.

Skyrizi also appeared to help those who didn’t benefit from prior treatment with Otezla. At the 52-week mark in the study, 72.3% of patients who failed to achieve an adequate Psoriasis Area and ...

How Quickly Will Skyrizi Work for Psoriatic Arthritis? If Skyrizi is working, your symptoms will start to improve over the first 1-2 months. Most people see the greatest improvements during the ...

Researchers from King’s College London (KCL) have investigated the early effects of AbbVie’s immunosuppressant drug, Skyrizi (risankizumab), which could help clinicians develop personalised treatment ...

Innovent’s psoriasis contender to IL-23 drugs like Tremfya and Skyrizi cleared skin and improved the severity of disease in a phase 3 test, setting up the company to seek approval from Chinese ...